Journal articleHuman
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Obstetrics and gynecology, 2019 Nov. Simon JA, Kingsberg SA, Portman D and 5 others.
Study type
Journal article
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Obstetrics and gynecology
Published
2019 Nov
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultCentral Nervous System AgentsFemaleHumansInjections, SubcutaneousLibidoLong Term Adverse EffectsPeptides, CyclicPsychological DistressReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4Retrospective Studies
Other papers on PT-141
Systematic review / meta-analysis · 2021
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women
Randomized controlled trial · 2019Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page